Correlation Between Eliem Therapeutics and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Eliem Therapeutics and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on Eliem Therapeutics and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and Acrivon Therapeutics,.

Diversification Opportunities for Eliem Therapeutics and Acrivon Therapeutics,

0.12

Correlation Coefficient

Eliem Therapeutics  Acrivon Therapeutics,

Average diversification

The 3 months correlation between Eliem and Acrivon is 0.12. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and Acrivon Therapeutics,

Given the investment horizon of 90 days Eliem Therapeutics is expected to generate 1.08 times less return on investment than Acrivon Therapeutics,. In addition to that, Eliem Therapeutics is 1.11 times more volatile than Acrivon Therapeutics, Common. It trades about 0.05 of its total potential returns per unit of risk. Acrivon Therapeutics, Common is currently generating about 0.06 per unit of volatility. If you would invest  476.00  in Acrivon Therapeutics, Common on August 16, 2024 and sell it today you would earn a total of  317.00  from holding Acrivon Therapeutics, Common or generate 66.6% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Eliem Therapeutics  vs.  Acrivon Therapeutics, Common

Eliem Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Acrivon Therapeutics,

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Acrivon Therapeutics, Common are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Acrivon Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in December 2024.

Pair Trading with Eliem Therapeutics and Acrivon Therapeutics,

The main advantage of trading using opposite Eliem Therapeutics and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind Eliem Therapeutics and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.